Showing 2081-2090 of 9336 results for "".
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in patients a…
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof,…
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg every two weeks for …
- Crayola Announces New "Colors of the World" Crayons To Help Advance "Skinclusion"https://practicaldermatology.com/news/crayola-announces-new-colors-of-the-world-crayons-to-help-advance-skinclusion/2460402/Crayola is launching Colors of the World crayons—24 new crayons designed to represent more than 40 global skin tones across the world. The crayon packs feature side panels that serve as color references. Each crayon is wrapped in a gradient skin tone label with the color name in English, Spanish a…
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive Global Solidarity Program to support employees, customers and communities affected by COVI…
- AAD: Sixty Percent of Americans Have Gotten Sunburned So Badly Their Clothes Were Uncomfortablehttps://practicaldermatology.com/news/aad-sixty-percent-of-americans-have-gotten-sunburned-so-badly-their-clothes-were-uncomfortable/2460396/Most Americans say they have gotten a sunburn and admit it has impacted their day-to-day life, according to a recent AAD survey. Of those who have been sunburned, 60 percent said their sunburns made their clothes uncomfortable; 43 percent said they couldn’t sleep; and 21 percent said they were emba…
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla (apremil…
- 2020 RealSelf Sun Safety Report: Majority of Americans Don’t Use Sunscreen Dailyhttps://practicaldermatology.com/news/realself-sun-safety-report-majority-of-americans-dont-use-sunscreen-daily/2460381/The recently released 2020 RealSelf Sun Safety Report found that 62 percent of Americans use anti-aging products as part of their daily skincare routine, but only 11 percent wear sunscreen daily and 46 percent never wear sunscreen. The report also revealed that while daily sunscreen use remains lo…
- Calling All Heroes: Cutera Seeks to Honor COVID-19 Championshttps://practicaldermatology.com/news/calling-all-heroes-cutera-seeks-to-honor-covid-19-champions/2460380/From physicians going back to the ER and conducting hospital rounds to supporting food depositories and shelters, to doctors donating personal protective equipment, ventilators, and office facilities as needed during the COVID-19 global pandemic, Cutera wants to shine a spotlight on its customers w…
- Supportive Oncodermatology Interventions Improve Patient Quality of Lifehttps://practicaldermatology.com/news/supportive-oncodermatology-interventions-improve-patient-quality-of-life-1/2460377/Enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score, according to a recent survey from the George Washington University (GW) Cancer Center. The results of the survey appear in the Journal of Drugs in Dermatology. Supportive oncoderm…